Upstream Bio, Inc.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
UPB$3.38-5.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(67,236) | $(25,572) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 85 | 26 |
| Stock-based compensation expense | 5,232 | 2,055 |
| Change in fair value of preferred stock tranche right liability | — | (2,859) |
| Net amortization of premiums and accretion of discounts on short-term investments | (2,720) | (1,765) |
| Non-cash lease expense | 272 | 43 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (324) | (412) |
| Prepaid expenses and other assets | (15,658) | 371 |
| Accounts payable | (1,456) | 3,062 |
| Accrued expenses and other current liabilities | 1,674 | (502) |
| Operating lease liabilities | (273) | (45) |
| Net cash used in operating activities | (80,404) | (25,598) |
| Cash flows from investing activities: | ||
| Purchases of short-term investments | (323,138) | (174,999) |
| Maturities of short-term investments | 122,577 | 72,197 |
| Purchases of equipment | (47) | — |
| Net cash used in investing activities | (200,608) | (102,802) |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of Series B redeemable convertible preferred stock, net of issuance costs paid | — | 149,924 |
| Payments of deferred offering costs | (34) | (133) |
| Proceeds from exercises of stock options | 612 | 112 |
| Net cash provided by financing activities | 578 | 149,903 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (280,434) | 21,503 |
| Cash, cash equivalents and restricted cash at beginning of period | 326,086 | 25,833 |
| Cash, cash equivalents and restricted cash at end of period | $45,652 | $47,336 |
| Cash, cash equivalents and restricted cash at end of period: | ||
| Cash and cash equivalents | $45,458 | $47,336 |
| Restricted cash | 194 | — |
| Total cash, cash equivalents and restricted cash at end of period | $45,652 | $47,336 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Settlement of Series B preferred stock tranche right liability | $— | $15 |
| Initial public offering costs included in accounts payable and accrued expenses | $— | $1,214 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.